We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

113 hedge funds and large institutions have $653M invested in Theravance Biopharma in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more call options, than puts

Call options by funds: $2.43M | Put options by funds: $947K

3.56% more ownership

Funds ownership: 92.13% → 95.69% (+3.6%)

5% less funds holding

Funds holding: 119 → 113 (-6)

6% less capital invested

Capital invested by funds: $696M → $653M (-$43.5M)

14% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 43

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

Holders
113
Holders Change
-6
Holders Change %
-5.04%
% of All Funds
1.8%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
10
Increased
37
Reduced
43
Closed
16
Calls
$2.43M
Puts
$947K
Net Calls
+$1.49M
Net Calls Change
-$10.1M

Top Buyers

1
ICM
Irenic Capital Management
New York
+$11.2M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$10.2M
3
Bank of America
Bank of America
North Carolina
+$9.5M
4
OM
Opaleye Management
Massachusetts
+$4.85M
5
OMC
Oasis Management Company
Cayman Islands
+$3.44M

Top Sellers

1
BG
Baupost Group
Massachusetts
-$10.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.03M
3
Two Sigma Investments
Two Sigma Investments
New York
-$6.41M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.9M
5
Millennium Management
Millennium Management
New York
-$5.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$113M -$10.6M -1,000,000 -9%
WAM
2
Weiss Asset Management
Massachusetts
$80.9M – – –
MAP
3
Madison Avenue Partners
New York
$76.1M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$61M +$718K +67,887 +1%
BlackRock
5
BlackRock
New York
$55.8M -$1.99M -188,100 -4%
ICM
6
Irenic Capital Management
New York
$30M +$11.2M +1,063,111 +63%
PWAM
7
Park West Asset Management
California
$20.6M -$213K -20,121 -1%
Bank of America
8
Bank of America
North Carolina
$19.3M +$9.5M +898,691 +102%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$18.6M -$8.03M -759,083 -31%
NM
10
Newtyn Management
New York
$16.6M +$857K +81,015 +6%
PAMS
11
Pictet Asset Management (Switzerland)
Switzerland
$15.8M +$10.2M +961,879 +195%
State Street
12
State Street
Massachusetts
$15.3M -$232K -21,911 -2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$12.9M +$479K +45,256 +4%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$11M -$5.9M -557,657 -35%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$11M -$229K -21,625 -2%
Northern Trust
16
Northern Trust
Illinois
$7.03M +$123K +11,674 +2%
C
17
Chescapmanager
Maryland
$6.76M -$2.41M -228,250 -27%
OMC
18
Oasis Management Company
Cayman Islands
$6.75M +$3.44M +325,316 +110%
OM
19
Opaleye Management
Massachusetts
$5.93M +$4.85M +458,704 +524%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$5.25M -$5.55M -524,800 -52%
Charles Schwab
21
Charles Schwab
California
$5.24M -$354K -33,516 -6%
Norges Bank
22
Norges Bank
Norway
$4.9M -$995K -94,089 -17%
Two Sigma Investments
23
Two Sigma Investments
New York
$3.87M -$6.41M -605,959 -63%
Morgan Stanley
24
Morgan Stanley
New York
$3.83M -$1.43M -134,920 -28%
Goldman Sachs
25
Goldman Sachs
New York
$3.65M -$101K -9,556 -3%
1
2 3 4 5

TBPH Hedge Fund Activity: Q1 2023 in Review

113 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2023, worth a combined $653M — down 6.3% from $696M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of TBPH and 10 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 37 added.

The largest buyer was Irenic Capital Management, adding an estimated $11.2M. The largest seller was Baupost Group, cutting an estimated $10.6M.

  • 113 institutional investors held Theravance Biopharma (TBPH) as of Q1 2023, down from 119 in Q4 2022.
  • Funds reported $653M of Theravance Biopharma stock for Q1 2023, down 6.3% quarter-over-quarter.
  • 10 funds opened new Theravance Biopharma positions in Q1 2023 and 16 closed out, a net change of -6 holders.
  • The largest Theravance Biopharma buyer in Q1 2023 was Irenic Capital Management, an estimated $11.2M added.
  • The largest Theravance Biopharma seller in Q1 2023 was Baupost Group, an estimated $10.6M sold.

Based on aggregated 13F filings for Q1 2023.